Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Transparency Policies Not Suited To Generics, GPhA Argues

Executive Summary

Legislation like FAIR drug pricing bill, which requires sponsors to justify price increases over 10%, could ultimately discourage generic competition since it could burden ANDA sponsors for even small dollar increases, GPhA CEO Davis argues.

You may also be interested in...



The US Drug Pricing Hearing Pharma Wants

Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.

The US Drug Pricing Hearing Pharma Wants

Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.

GPhRMA? Generic Trade Group Picks Up Another Exec From Brand Association

PhRMA Senior Counsel Jeffrey Francer will become GPhA's General Counsel in mid-November.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel